AIM Comments on FDA’s Patient-Focused Drug Development Initiative
The AIM Coalition has provided a response to the Food and Drug Administration’s (FDA) request for comments about its patient-focused drug development initiative. In its response, AIM thanked the FDA and the Center for Drug Evaluation and Research for including sarcopenia as one of the diseases being considered for a patient-focused drug development meeting for FY 2016-17. It also encouraged that sarcopenia be prioritized for a meeting due to its impact on the aging population. You can read the letter here.